3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
Azacitidine
66
venetoclax
21
Decitabine
16
Cytarabine
12
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
7
fludarabine
6
pevonedistat
5
mocetinostat
5
ON 01910
5
Busulfan
5
treosulfan
4
sabatolimab
4
ruxolitinib
4
cedazuridine
4
cc-486
4
Mycophenolic Acid
4
Lenalidomide
4
Injections
4
plerixafor
3
luspatercept
3
imetelstat
3
glasdegib
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Methotrexate
3
GRN163L peptide
3
Clofarabine
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myelodysplastic Syndromes
×
Standard of Care
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts